Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLRBNASDAQ:PHIONASDAQ:RGLSNASDAQ:SLRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$3.05-0.3%$3.65$1.33▼$4.45$98.39M0.921.65 million shs531,472 shsPHIOPhio Pharmaceuticals$0.68+0.7%$0.80$0.50▼$6.85$3.10M1.44367,560 shs97,756 shsRGLSRegulus Therapeutics$2.29+3.2%$2.17$1.08▼$3.79$149.90M1.572.42 million shs68,599 shsSLRXSalarius Pharmaceuticals$0.48-6.1%$0.56$0.43▼$2.31$2.28M1.0197,225 shs3,485 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-1.61%-4.67%-20.93%-14.76%+106.76%PHIOPhio Pharmaceuticals-4.25%+4.60%-11.71%+11.83%-79.97%RGLSRegulus Therapeutics-1.77%-5.13%-21.28%+74.80%+63.24%SLRXSalarius Pharmaceuticals+1.40%+4.53%+3.25%-2.50%-69.02%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences2.1842 of 5 stars3.54.00.00.02.50.00.6PHIOPhio Pharmaceuticals2.1384 of 5 stars3.53.00.00.00.92.50.6RGLSRegulus Therapeutics2.4 of 5 stars4.42.00.00.02.01.70.0SLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences3.00Buy$20.00555.74% UpsidePHIOPhio Pharmaceuticals3.00Buy$4.00491.80% UpsideRGLSRegulus Therapeutics2.80Moderate Buy$7.25216.59% UpsideSLRXSalarius Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest RGLS, PHIO, CLRB, and SLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.002/6/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A($0.36) per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/ARGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ASLRXSalarius Pharmaceuticals$1.84M1.24N/AN/A$1.34 per share0.36Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$37.98M-$3.10N/AN/AN/AN/A-3,821.29%-280.23%5/2/2024 (Estimated)PHIOPhio Pharmaceuticals-$10.83M-$5.93N/A∞N/AN/A-134.66%-105.86%5/9/2024 (Estimated)RGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)SLRXSalarius Pharmaceuticals-$12.54M-$4.53N/AN/AN/AN/A-197.96%-135.23%5/9/2024 (Estimated)Latest RGLS, PHIO, CLRB, and SLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023CLRBCellectar Biosciences-$0.59-$0.66-$0.07-$0.92N/AN/A3/22/2024Q4 2023SLRXSalarius Pharmaceuticals-$1.01-$0.22+$0.79-$0.22N/AN/A3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A0.810.81PHIOPhio PharmaceuticalsN/A5.705.71RGLSRegulus TherapeuticsN/A3.313.31SLRXSalarius PharmaceuticalsN/A5.025.02OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%PHIOPhio Pharmaceuticals57.31%RGLSRegulus Therapeutics92.38%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences4.60%PHIOPhio Pharmaceuticals0.77%RGLSRegulus Therapeutics8.41%SLRXSalarius Pharmaceuticals5.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences2032.26 million30.78 millionOptionablePHIOPhio Pharmaceuticals94.59 million4.56 millionNot OptionableRGLSRegulus Therapeutics3065.46 million59.96 millionOptionableSLRXSalarius Pharmaceuticals24.78 million4.08 millionNot OptionableRGLS, PHIO, CLRB, and SLRX HeadlinesSourceHeadlineSLRX Pursues Important Goalfinance.yahoo.com - April 2 at 1:44 PMWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Datamsn.com - March 27 at 1:54 AMWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarketmsn.com - March 25 at 11:52 AMSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 23 at 8:07 AMSalarius: Q4 Earnings Snapshotsfgate.com - March 22 at 4:56 PMSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 22 at 4:05 PMQuoin stock craters 47% on public offering after rallying in prior sessionmsn.com - March 5 at 2:32 PMQuoin stock soars 60% on FDA update for ichthyosis drugmsn.com - March 4 at 12:43 PMSalarius Pharmaceuticals Implements Cost-savings Measuresmarkets.businessinsider.com - February 22 at 1:52 PMSalarius's CEO David Arthur steps downmsn.com - February 22 at 8:52 AMSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expensesfinance.yahoo.com - February 22 at 8:52 AMSalarius Pharmaceuticals Inc (SLRX)uk.investing.com - February 9 at 12:58 AMSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degradersfinance.yahoo.com - January 16 at 1:35 PMSquare Pharmaceuticals Ltd.wsj.com - January 13 at 3:02 PMInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollmentfinance.yahoo.com - January 3 at 9:32 AMSLRX Continues Work as it Seeks Alternativesfinance.yahoo.com - November 10 at 4:03 PMSalarius Pharmaceuticals Inc SLRXmorningstar.com - November 8 at 8:37 AMSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Programfinance.yahoo.com - November 7 at 10:25 AMSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsbizjournals.com - August 10 at 6:57 PMSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - August 10 at 6:57 PMSLRX Pursuing Strategic Alternativesfinance.yahoo.com - August 9 at 3:15 PMSalarius Pharmaceuticals lays off over 50% of staff in search for strategic alternativesendpts.com - August 9 at 10:15 AMWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price Targetbenzinga.com - July 11 at 5:51 PMSLRX Continues Cancer Fight with Phase I Trial Approvalfinance.yahoo.com - July 11 at 5:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Salarius PharmaceuticalsNASDAQ:SLRXSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.